Danavorexton

N/A

Report date: 2025/02/18 11:52:49
NME

Base Information

Drug NameDanavorexton
Drug Alias NameTAK-925
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionOrexin receptor type 2 agonists
TargetsOrexin receptor type 2
Therapy Area/IndicationsDelayed Emergence from AnesthesiaNarcolepsyIdiopathic Hypersomnia +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaJapan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceutical Co Ltd
Inactive CompaniesMillennium Pharmaceuticals Inc
Active IndicationsDelayed Emergence from AnesthesiaSleep Apnea SyndromesRespiration Disorders
Inactive IndicationsNarcolepsyIdiopathic HypersomniaSleep Apnea, Obstructive

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank